[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":218},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,41,64,86,110,131,155,176,196],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100550619","use-of-propofol-as-a-sedative-agent-versus-spinal-analgesia-with-bupivacaine-in-external-cephalic-version-100550619",false,"NCT06449430","Use of Propofol as a Sedative Agent Versus Spinal Analgesia With Bupivacaine in External Cephalic Version","Randomized Clinical Trial of the Use of Propofol as a Sedative Agent Versus Spinal Analgesia With Bupivacaine in External Cephalic Version","PropoSpinECV","Inclusion Criteria:\n\n* Voluntary participation.\n* Older than 18 years.\n* Non-cephalic presentation.\n* Desire to attempt a vaginal birth.\n* Normal blood count and coagulation prior to the intervention\n\nExclusion Criteria:\n\n* Age under 18 years old.\n* Multiple gestation.\n* Cephalic presentation.\n* Risk of fetal compromise.\n* Unexplained active bleeding.\n* Absolute contraindication for vaginal delivery (Placenta Previa)\n* 2 or more previous cesarean sections.\n* Previous myomectomy with entry into the uterine cavity\n* Maternal fever.\n* Thrombocytopenia (\\\u003C85,000 platelets).\n* Maternal spinal anomaly.\n* Intolerance or allergy to Propofol or any of its components.\n* Intolerance or allergy to bupivacaine or any of its components.\n* Contraindication for intrathecal sedation or analgesia","FEMALE","18 Years",{"count":20,"type":21},270,"ESTIMATED","INTERVENTIONAL",[24],"NA","External Cephalic Version (ECV) is a maneuver to modify fetal position in pregnant women with a non-cephalic presentation. Its objective is to achieve a cephalic presentation that allows for vaginal delivery with less risk than a vaginal breech delivery or a cesarean section. ECV is an effective technique to reduce the rate of cesarean sections and is recommended by the Spanish Society of Obstetrics and Gynecology (SEGO) and the World Health Organization (WHO) Cesarean Section Working Group. The WHO aims to reduce interventionism in childbirth globally and implement non-clinical measures to reduce the rate of unnecessary cesarean sections.\n\nDespite Propofol is a sedative agent commonly used by anesthesiologist in countless ambulatory procedures in obstetric anaesthesia, it has been little studied in ECV, and its effect has not been compared with other commonly used agents such as remifentanil or spinal analgesia. The Obstetric Anesthesiology Section of the Spanish Society of Anesthesiology and Resuscitation recommends the use of locoregional analgesia in ECV.",[27],"Pregnancy Complications","RECRUITING","2025-11-18",{"date":31,"type":32},"2025-11-21","ACTUAL",{"date":34,"type":32},"2024-07-06",{"date":36,"type":21},"2027-11-30",{"name":38,"class":39},"Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":48,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":40},"100597924","standardized-resistance-training-program-and-assessment-system-for-prostate-cancer-patients-receiving-androgen-deprivation-therapy-isport-pca-adt-study-protocol-for-a-randomized-controlled-trial-sport-mu-100597924","NCT07064811","Standardized Resistance Training Program and Assessment System for Prostate Cancer Patients Receiving Androgen Deprivation Therapy ISPoRT-PCa-ADT Study Protocol for a Randomized Controlled Trial. SPORT-MU","SPORT-MU","Inclusion Criteria:\n\n* diagnosis of locally advanced or metastatic prostate neoplasm and current treatment with androgen deprivation therapy (ADT)\n* treatment at the radiotherapy oncology department of University Clinical Hospital \"Virgen de la Arrixaca\"\n* legal adult age with signed informed consent\n\nExclusion Criteria:\n\n* unwillingness to participate in the study\n* inability to complete adequate follow-up due to any cause that would prevent knowledge of patient evolution during the follow-up period\n* no controlled or symptomatic metastatic bone disease\n* physical disabilities that would prevent participants from safely completing the exercise protocol","MALE",{"count":50,"type":21},60,[24],"This randomized controlled trial (RCT) with two parallel study arms evaluated the effectiveness of a 24-week exercise intervention in prostate cancer (PCa) patients under-going androgen deprivation therapy (ADT). Ethical approval was obtained from the Clinical Research Ethics Committee of the University Clinical Hospital \"Virgen de la Arrixaca\" (Murcia, Spain). Participants were randomly assigned to one of two groups: (1) a supervised progressive resistance training program (SPoRT-PCa-ADT), or (2) a control group receiving a home-based exercise protocol following an initial assessment, accom-panied by weekly telephone follow-up. Assessments were conducted at baseline and at 24 weeks to examine changes in physical, functional, and psychosocial outcomes. Addi-tionally, patient-reported outcomes were collected at the 12-week midpoint (Figure 1). This study design enabled the evaluation of both immediate and sustained intervention effects and facilitated a direct comparison between supervised and home-based exercise approaches",[54],"Prostate Cancer","NOT_YET_RECRUITING","2025-07-07",{"date":58,"type":32},"2025-07-15",{"date":60,"type":21},"2025-11-15",{"date":62,"type":21},"2027-02-15",{"name":38,"class":39},{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":22,"phases":74,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":40},"100585446","combined-intraperitoneal-chemotherapy-regimen-after-optimal-interval-surgery-in-advanced-ovarian-cancer-bicov-1-bidirectional-chemotherapy-in-ovarian-cancer-100585446","NCT06902467","Combined Intraperitoneal Chemotherapy Regimen After Optimal Interval Surgery in Advanced Ovarian Cancer: BICOV-1 (Bidirectional Chemotherapy in Ovarian Cancer)","BICOV","Inclusion Criteria:\n\n* Women aged 18-70 years with a histologically proven diagnosis of FIGO stage IIIB-C\u002FIV epithelial ovarian cancer (high-grade serous epithelial carcinoma)\n* Absence of extraperitoneal disease.\n* Good performance status: Karnofsky score \\>70 or Performance status \\\u003C= 2\n* Adequate liver function, defined as bilirubin \\\u003C0.15 times the upper limit of normal (ULN), aspartate aminotransferase and alanine aminotransferase \\\u003C= 2.5 times ULN, and alkaline phosphatase \\\u003C= 3 times ULN.\n* Adequate renal function, defined as serum creatinine \\\u003C= 1.5 times ULN\n* Acceptable bone marrow function, defined as neutrophils \\>1.5 x 106 L-1, hemoglobin \\>10 g\u002FdL-1, and platelets \\>100.0 x 109 L-1\n* Absence of cardiac, pulmonary, hepatic, renal, or neurological disease that contraindicates major surgery.\n* Negative serum and urine pregnancy test results for women of childbearing potential at the screening visit.\n* Administration of neoadjuvant chemotherapy with a total of 3 or 4 systemic cycles.\n* Surgery with complete CC0 cytoreduction without digestive anastomoses.\n* Patients who have signed the written IC.\n\nExclusion Criteria:\n\n* Disease progression during systemic treatment with neoadjuvant chemotherapy.\n* Extraperitoneal disease (including retroperitoneal lymph node metastases)\n* Inability to achieve complete cytoreduction (CC-0) during preoperative (imaging) or intraoperative evaluation.\n* Performance of at least one digestive anastomosis of any type. Active infection of any origin\n* Allogeneic transplant, or prior bone marrow transplant, or high-dose chemotherapy with bone marrow or stem cell rescue.\n* Participation in a clinical trial with an investigational drug within the last 30 days.\n* Pregnant or breastfeeding women, where pregnancy is defined as the state of a woman after conception and until the end of pregnancy, confirmed by a positive human chorionic gonadotropin (hCG) test result, or who plan to become pregnant or breastfeed during study treatment or within 30 days of the end of treatment with the study drug.\n* Patients with a history of allergic reactions or hypersensitivity to drugs chemically related to cisplatin and paclitaxel.\n* Failure to sign written informed consent.","70 Years",{"count":73,"type":21},20,[24],"A multicenter, low-intervention, drug-based study to evaluate the feasibility and safety of a combined regimen of two intraperitoneal chemotherapy modalities (used in routine clinical practice) following interval surgery for the treatment of advanced ovarian cancer. This is an independent research project (free of commercial interests).",[77],"Ovarian Cancer","2025-03-28",{"date":80,"type":32},"2025-03-30",{"date":82,"type":32},"2023-02-27",{"date":84,"type":21},"2026-12-15",{"name":38,"class":39},{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":93,"minAge":18,"maxAge":4,"enrollmentInfo":94,"targetDuration":96,"studyType":97,"phases":4,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":40},"100585161","creation-of-a-national-multicenter-platform-for-the-study-of-inflammatory-myocardial-disease-pre-myo-cohort-100585161","NCT06898762","Creation of a National Multicenter Platform for the Study of Inflammatory Myocardial Disease: Pre-MYO Cohort","PREMYO","Inclusion Criteria:\n\n• Presence of at least one compatible symptom and at least one objective finding in diagnostic tests (Figure 2), according to the consensus document of the European Society of Cardiology (1):\n\nA. Clinical presentation:\n\n* Acute chest pain: pericardial or pseudo-ischemic.\n* Dyspnea on exertion or at rest for up to 3 months.\n* Dyspnea on exertion or at rest for 3 months - 1 year.\n* Unexplained palpitations \u002F arrhythmias, sudden death recovered.\n* Unexplained cardiogenic shock.\n\nB. Findings in complementary tests:\n\n* ECG: new onset AV block, new onset bundle branch block, ST segment elevation\u002Fdepression, T wave inversion\n* Elevation of TnI\u002FTnT\n* Segmental or global contractility alterations not explained by other causes\n* Positive Lake Louise criteria in cardiac MRI (13) (Annex III Figure S1) • Patients who have given their informed consent.","ALL",{"count":95,"type":21},3000,"3 Years","OBSERVATIONAL","The objectives of this project are: 1) to comprehensively characterize a large national cohort of patients with suspected myocarditis, their clinical phenotype, care management, blood and imaging biomarkers, epidemiological, environmental and genetic data; 2) to retrospectively validate the accuracy of the new hsa-RNA-Chr8:96 biomarker for the diagnosis of myocarditis compared to conventional diagnosis; 3) to identify acquired and inherited mutations, and their interaction with the environment, which explain the susceptibility to myocarditis, its severity and response to treatment; 4) to study the lower incidence in women and the influence of age, considering socio-health and genetic factors.",[100,101],"Myocarditis Acute","Inflammatory Cardiomyopathy","2025-03-21",{"date":104,"type":32},"2025-03-27",{"date":106,"type":32},"2023-04-09",{"date":108,"type":21},"2028-12-31",{"name":38,"class":39},{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":117,"targetDuration":119,"studyType":97,"phases":4,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":40},"100583329","first-trimester-prediction-of-gestational-diabetes-mellitus-by-continuous-glucose-monitoring-100583329","NCT06874907","First Trimester Prediction of Gestational Diabetes Mellitus by Continuous Glucose Monitoring.","GLUCO-GCM","Inclusion Criteria:\n\n* Maternal age ≥ 18 years\n* Planned antenatal care at the same centre (i.e. not planning to move before delivery).\n* Singleton pregnancy.\n* Informed and written consent.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years;\n* Multiple pregnancy in current pregnancy;\n\n  * Unconscious or very ill; · Serious mental illness;\n  * Learning difficulties;\n  * Not fluent in local language and absence of interpreter;\n  * Severe congenital anomaly on ultrasound;\n  * Pre-existing diabetes mellitus type 1 or 2;\n  * Patients undergoing metformin therapy for infertility.\n  * Significant pre-pregnancy comorbidities that increase risk in pregnancy, for example renal failure, severe liver disease, transplantation, cardiac failure, psychiatric conditions requiring in-patient admission (\\\u003C1 year);\n  * Significant co-morbidity in the current pregnancy, nephropathy (estimated GFR \\\u003C60ml\u002Fmin), other physical or psychological conditions likely to interfere with the conduct of the study and\u002For interpretation of the trial results;\n  * Participating in another intervention study that influences outcomes of this study;\n  * Allergy to adhesive materials;\n  * Allergy to any of the components of the glucose test:",{"count":118,"type":21},1000,"2 Years","Gestational diabetes mellitus (GDM) is the most common complication of pregnancy, with an incidence rate of 10-15% \\[1\\]. Common risk factors for GDM are increased maternal age and weight and as a consequence of women delaying childbirth and increasing incidence of obesity, there is a corresponding increase in the rate of GDM. GDM is associated with an increased risk of maternal and perinatal short and long-term complications . These include macrosomia, shoulder dystocia, neonatal hypoglycaemia, neonatal hyperbilirubinemia, and perinatal mortality. Maternal complications include higher risks of hypertensive disorders, perineal trauma, and caesarean section. Additionally, both the mothers with GDM and their infants have an increased risk of developing type 2 diabetes mellitus and cardiovascular disease later in life .\n\nScreening and diagnosis of GDM is currently based on an oral glucose tolerance (OGTT), which is carried out at 26-28 weeks' gestation. In addition, an OGTT is carried out at 11-13 weeks in women considered to be at increased risk of GDM based on their demographic characteristics and medical history. Screening and diagnosis of GDM is traditionally delayed until the late second or early third trimester of pregnancy with the rationale that the diabetogenic effects of pregnancy increase with gestation and therefore delayed testing would maximize the detection rate.",[122],"Gestational Diabetes Mellitus in Pregnancy","2025-03-10",{"date":125,"type":32},"2025-03-13",{"date":127,"type":32},"2025-03-01",{"date":129,"type":21},"2026-07-01",{"name":38,"class":39},{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":93,"minAge":138,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":22,"phases":141,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":154},"100565775","phase-4-long-acting-cabotegravir-plus-rilpivirine-in-people-living-with-hiv-1-aged--60-years-for-24-months-100565775","NCT06646562","Long Acting Cabotegravir Plus Rilpivirine in People Living with HIV-1 Aged ≥ 60 Years for 24 Months.","LOVER60","Inclusion Criteria:\n\n* Be able to understand and comply with protocol requirements, instructions, and restrictions.\n* Understand the long-term commitment to the study and be likely to complete the study as planned.\n* Be considered appropriate candidates for participation in an investigative clinical trial with oral and intramuscularly injectable medications (e.g., no active substance use disorder, acute major organ disease, or planned long-term work assignments out of the country, etc.).\n* Must be on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class.\n* Plasma HIV-1 RNA \\\u003C50 copies\u002FmL at screening.\n* A female subject is eligible to participate if she is not pregnant (as confirmed by a negative serum hCG test at screen and a negative urine hCG test at randomization) and not lactating\n\nExclusion Criteria:\n\n* Plasma HIV-1 RNA measurement ≥50 copies\u002FmL within 6 months prior to screening. Blips are allowed (increased viral load ≥50 copies\u002FmL but \\\u003C200 copies\u002FmL preceded and followed by a viral load less than 50 copies\u002FmL)\n* Any drug holiday during the window between initiating first HIV ART and 6 months prior to screening, except for brief periods (less than 1 month) where all ART was stopped due to tolerability and\u002For safety concerns.\n* Any switch to a second line regimen, defined as change of a single drug or multiple drugs simultaneously, due to virologic failure to NNRTI or INSTI (defined as a confirmed plasma HIV-1 RNA measurement ≥200 copies\u002FmL after initial suppression to \\\u003C50 copies\u002FmL while on first line HIV therapy regimen)\n* Subjects who are currently participating in or anticipate being selected for any other interventional study. Observational studies and intervention studies that do not include treatments are allowed unless they interfere with scheduled visits.\n* Participants receiving any prohibited medication and who are unwilling or unable to switch to an alternative medication","60 Years",{"count":140,"type":21},120,[142],"PHASE4","People Living with HIV-1 (PLHIV) are an important group of patients attending their specialist's and continue growing thanks to efficacy antiretroviral treatment (ART), allowing them to stabilize the HIV-infection and to live a normal life despite the infection. The present study is encouraged to demonstrate that efficacy and security of CAB LA + RPV LA treatment's on this population remains the same compared to younger population of patients. This study also registers some metabolic and hepatic parameters to observe a hypothetical improvement on these parameters, as the population may suffer more comorbidities than younger population and therefore tolerability and convenience gains a huge importance on them. Psychosocial aspects are also very important in these patients as these patients may suffer social stigma, and therefore suffering certain psychological disorders.",[145],"HIV-1 Infected Adults with Controlled Viremia","2025-03-06",{"date":148,"type":32},"2025-03-11",{"date":150,"type":32},"2025-03-03",{"date":152,"type":21},"2027-01-30",{"name":38,"class":39},8,{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":162,"targetDuration":164,"studyType":97,"phases":4,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":40},"100582056","study-of-maternal-and-fetal-cardiovascular-function-in-hypertensive-states-of-pregnancy-100582056","NCT06858345","Study of Maternal and Fetal Cardiovascular Function in Hypertensive States of Pregnancy","CARDIAC-OAT","Inclusion Criteria:\n\n* Age greater than or equal to 18 years\n* Women with singleton and twin pregnancies complicated by hypertensive states of pregnancy.\n\nExclusion Criteria:\n\n* Minors under 18 years of age.\n* Women with mental disabilities.\n* Major congenital fetal anomaly.",{"count":163,"type":21},50,"1 Year","The pharmacological treatment strategy is then tailored to the underlying hemodynamic phenotype of each patient. That is, rather than applying a one-size-fits-all treatment for all patients, therapy is tailored to the specific characteristics of how the cardiovascular system functions in each patient (e.g., whether the problem is more related to blood volume, vascular resistance, cardiac output, etc.). The goal is to personalize therapy to more effectively treat hypertensive states of pregnancy.",[167],"Preeclampsia","2025-02-27",{"date":170,"type":32},"2025-03-05",{"date":172,"type":32},"2025-01-01",{"date":174,"type":21},"2026-01-15",{"name":38,"class":39},{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":22,"phases":184,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":40},"100578779","multicenter-study-on-the-correction-of-prolapse-via-laparoscopy-100578779","NCT06815731","Multicenter Study on the Correction of Prolapse Via Laparoscopy","Inclusion Criteria:\n\n* Patients with Stage II- IV primary or recurrent prolapse affecting the anterior or middle vaginal compartment with or without minimal posterior defect (Stage I) according to the POP-Q.\n\nExclusion Criteria:\n\n* History of abdominal prolapse reconstructive surgery.\n* History of prolapse reconstructive surgery with vaginal meshes.\n* Stage I according to the POP-Q classification or asymptomatic prolapse.\n* Medical contraindication for general anaesthesia.\n* Patient preference for vaginal surgical treatment.\n* Patient does not wish to participate in the study.",{"count":183,"type":21},181,[24],"In the laparoscopic lateral suspension (LLS) technique, the fixation of the mesh as a prosthetic element for correcting anterior apical vaginal prolapse at the level of the dome or uterus can offer anatomical and functional results that are not inferior to those of the conventional surgical technique, minimize possible intraoperative complications and facilitate the specific learning curve of sacropexy.",[187],"Pelvic Floor Disorders","2025-02-06",{"date":190,"type":32},"2025-02-07",{"date":192,"type":32},"2023-10-01",{"date":194,"type":21},"2026-05-30",{"name":38,"class":39},{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":200,"acronym":201,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":93,"minAge":203,"maxAge":204,"enrollmentInfo":205,"targetDuration":4,"studyType":22,"phases":206,"briefSummary":207,"conditions":208,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":40},"100570918","efficacy-of-self-titration-of-ventilation-in-overlap-syndrome-chronic-obstructive-pulmonar-disease--sleep-apnea-syndrome--with-dynamic-hyperinflation-edin-idin-100570918","NCT06713486","Efficacy of Self-titration of Ventilation in Overlap Syndrome (chronic Obstructive Pulmonar Disease + Sleep Apnea Syndrome ) with Dynamic Hyperinflation. EDIN-IDIN.","EDIN-IDIN","Inclusion Criteria:\n\n* Stability of at least 4 weeks without hospital admission.\n* Previously presented PCO2 \\> 52.\n* Age between 50 and 80 years.\n* Agree to participate in the study and sign the informed consent.\n* Both sexes.\n\nExclusion Criteria:\n\n* Refusal to participate in the study.\n* Uncontrolled structural or coronary heart disease (no changes in medication in the last 15 days).\n* LVEF \\\u003C 45%.\n* Central sleep apnea syndrome (≥ 50% central events).\n* Uncontrolled pulmonary hypertension.\n* Inability to perform the tests.\n* Having had an exacerbation 4 weeks prior.\n* Severe psychiatric illness.\n* Cognitive impairment.\n* Not speaking Spanish.\n* Illiteracy.\n* Active smoker (or \\\u003C 6 months since quitting smoking).","50 Years","80 Years",{"count":73,"type":21},[24],"The combination of COPD and obstructive sleep apnea (OSA) can lead to undesirable interactions with the treatment approach. The investigators know that continuous positive airway pressure (CPAP) can increase dynamic hyperinflation in COPD patients, and in mechanical ventilation, the increase in PEEP can worsen dynamic hyperinflation. On the other hand, the team know that the severity of COPD obstruction and hyperinflation alter sleep efficiency, with periods of wakefulness during sleep, and during these periods, the patient would not have upper airway obstruction, which could affect the therapy they are receiving in CPAP mode for OSA. Moreover, it was observed that with greater hyperinflation, the rate of obstructive events decreases, dynamically affecting the ventilatory situation with upper airway resistance. Recent studies have determined the safety and efficacy of auto-adjusting systems in the treatment of overlap syndrome, which could be more adaptable to the changing pulmonary mechanics of these patients. Aerobic capacity is a good predictor to the health status in these patients and the investigators know it is reduced in patients with AOS, where CPAP treatment according to studies improves the peak VO2. Therefore, the objective is to compare a ventilation system with fixed pressures established through polysomnography in patients with overlap syndrome and dynamic hyperinflation to a dynamic ventilation system using the fixed pressure limits typically established, based on their impact on the aerobic capacity (peak VO2) of these patients after 1 month of treatment.",[209],"Pulmonary Disease, Chronic Obstructive","2024-11-27",{"date":212,"type":32},"2024-12-03",{"date":214,"type":21},"2024-12-01",{"date":216,"type":21},"2026-09-01",{"name":38,"class":39},""]